Cargando…
Circulating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients
AIM: Radium-223 improves overall survival in patients with metastatic castration-resistant prostate cancer to the bone. Radium-223 causes double-strand DNA breaks and produces γH2AX, a potential biomarker for response. We examined the feasibility of tracking γH2AX positivity and numeration in circul...
Autores principales: | Chatzkel, Jonathan, Mocha, Jesse, Smith, Johnna, Zhou, Jun-Min, Kim, Youngchul, El-Haddad, Ghassan, Zhang, Jingsong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920735/ https://www.ncbi.nlm.nih.gov/pubmed/31915536 http://dx.doi.org/10.2144/fsoa-2019-0092 |
Ejemplares similares
-
Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015) -
Radium 223 dichloride for prostate cancer treatment
por: Deshayes, Emmanuel, et al.
Publicado: (2017) -
(18)F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with (223)Ra-chloride (Alpharadin)
por: Cook, Gary JR, et al.
Publicado: (2011) -
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)